AN2 Therapeutics, Inc. (ANTX )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol ANTX
- Company AN2 Therapeutics, Inc.
- Price $2.85
- Changes Percentage 66.67
- Change 1.14
- Day Low $1.57
- Day High $2.96
- Year High $2.97
- Year Low $1
- Market Cap $78,095,768
- Price Avg 50 EMA (D) $1.14
- Price Avg 200 EMA (D) $1.15
- Exchange NASDAQ
- Volume 6,719,148
- Average Volume 120,070
- Open $1.71
- Previous Close $1.71
- EPS -1.13
- PE -2.52
- Earnings Announcement 2026-04-01 12:00:00
- Shares Outstanding $27,402,024
Company brief: AN2 THERAPEUTICS, INC. (ANTX )
- Healthcare
- Biotechnology
- Mr. Eric E. Easom
- https://www.an2therapeutics.com
- US
- N/A
- 03-25-2022
- US0373261058
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.